查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466461

放射性藥物市場：按類型、手術數量和應用分類 - 2024-2030 年全球預測

Radiopharmaceuticals Market by Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine), Procedural Volume (Diagnostic Procedures, Therapeutic Procedures), Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

放射性藥物市場規模預計2023年為51.5億美元，2024年達到54.8億美元，預計2030年將達到80億美元，複合年成長率為6.47%。

放射性藥物是一類獨特的含有放射性同位素的藥物製劑，用於核醫領域。這些化合物具有發射輻射的能力，可用於多種用途，包括診斷、治療和研究。放射性藥物在疾病檢測和治療、增加早期診斷、監測疾病進展和提高治療性介入的有效性方面具有重要價值。由於癌症和心血管疾病等需要先進診斷技術的慢性疾病盛行率不斷上升，放射性藥物的普及正在顯著增加。 PET 和 SPECT 等成像技術的進步也推動了放射性藥物市場的成長。此外，個人化醫療和標靶治療方法的日益採用也推動了對治療應用的放射性同位素的需求。儘管預計將出現可觀的成長，但放射性藥物市場面臨挑戰，例如嚴格的監管要求，導致新放射性藥物的核准非常耗時。開發和製造放射性藥物的高昂成本以及對專業設施和訓練有素的人員的需求增加了該行業面臨的挑戰。然而，不斷增加的研發投資為放射性藥物市場的創新和擴展提供了充足的機會。此外，將診斷和治療功能結合到單一藥物中的治療診斷學的進步為綜合醫療解決方案和個人化治療提供了新途徑，為放射性藥物市場的持續成長奠定了基礎。

主要市場統計
基準年[2023] 51.5億美元
預測年份 [2024] 54.8億美元
預測年份 [2030] 80億美元
複合年成長率（%） 6.47%

治療量：近距離放射治療中同位素治療的進展

放射性藥物在現代醫學的診斷和治療方面都發揮著至關重要的作用。包括 PET 和 SPECT 放射性藥物在內的診斷程序的程序量仍然很重要，因為它們在準確的疾病檢測和監測方面具有重要的能力。 PET 掃描使用發射正子的放射性藥物來提供代謝活動和血流等過程的高解析度功能影像。相較之下，SPECT 使用發射伽馬射線的放射性藥物來繪製生理功能圖。在治療過程中，α發射核素由於其高線性能量轉移和短距離，可有效治療微轉移。 BETA發射核素具有更好的組織滲透性，使其適合治療大量患病細胞。近距離放射治療同位素療法涉及將放射源直接植入腫瘤內或腫瘤附近，提供局部放射治療，對周圍健康組織的影響最小。

應用：增加放射性藥物在治療方法的使用

正子斷層掃描 (PET) 透過詳細顯示心肌灌注和代謝，在心臟病學中發揮重要作用。 PET 可用於診斷各種心臟疾病，包括冠狀動脈疾病、評估心肌活力以及監測治療後的心肌健康狀況。在神經病學中，PET 可提供有關腦血流、葡萄糖代謝和胺基酸攝取的寶貴見解。 PET 影像廣泛用於評估神經退化性疾病，如帕金森氏症、癲癇和阿茲海默症。它在個人化神經病學患者照護中發揮著重要作用，因為它有助於早期診斷、追蹤疾病進展和評估治療性介入。 PET 影像由於能夠靈敏地檢測癌症並對其進行分期，因此在腫瘤學中極為重要。它對於定位腫瘤、了解代謝活動和評估治療反應很有用。 PET 研究指南癌症治療的臨床決策，包括手術治療計劃、放射治療和新化療方案的評估，並為腫瘤干預提供了途徑。

單光子放射電腦斷層掃描通常用於心臟影像，以評估血流並檢查心臟的泵血功能。檢測缺血和梗塞區域並協助臨床醫生規劃干預措施。 SPECT 影像在淋巴瘤患者的分期和後續觀察中發揮重要作用。 SPECT可以找出淋巴結的精確位置並評估疾病的擴散情況，這對於調整治療方法至關重要。在神經病學中，SPECT 可以分析腦血流並評估神經細胞的完整性。它用於評估中風、失智症和癲癇等疾病，並可用於確定功能障礙和治療效果。 SPECT 對於甲狀腺影像特別有用，可用於評估結節的存在和性質以及甲狀腺功能亢進的情況。它提供有關甲狀腺活動的功能資訊，可用於甲狀腺癌患者的管理，包括術後評估和轉移檢測。

放射性藥物在骨轉移的姑息治療中發揮著至關重要的作用，其中轉移性癌細胞已擴散到骨骼。向患者施用諸如鍶89和釤153之類的放射性化合物，選擇性地定位於骨轉換增加的區域，並施用局部放射以減輕疼痛并提供鴉片類鎮痛劑，可以減少對藥物的需求。放射性藥物的使用已經改變了內分泌腫瘤（例如神經內分泌腫瘤（NET））的治療。胜肽受體放射性核種療法（PRRT）使用放射性標記的生長抑制素類似物（例如鎦-177 dotatate），靶向癌細胞上的生長抑制素受體，並將細胞毒性輻射直接傳遞到腫瘤。淋巴瘤，特別非何傑金氏淋巴瘤(NHL) 的放射性藥物治療採用放射性標記的單株抗體，靶向惡性細胞表面的 CD20 抗原。與釔 90 結合的 ibritumomab tiuxetan (Zevalin) 等藥物可以對癌細胞進行標靶放射治療，對於對傳統化療有抵抗力或尋求不太積極的治療方法。使用 iodine-131 進行放射性碘治療是治療甲狀腺亢進和分化型甲狀腺癌的既定治療方法。這種有針對性的方法對於分化型甲狀腺癌的術後​​管理至關重要，並且對於治療和影像都很有用。

區域洞察

在核子醫學和先進醫療基礎設施進步的推動下，美洲放射性藥物市場呈現強勁成長。美國由於研發投入大、報銷政策優惠，對市場貢獻大。由於意識的提高和醫療保健設施的改善，加拿大和拉丁美洲也在成長，儘管速度較慢。歐洲是歐洲、中東和非洲地區放射性藥物市場的主要貢獻者，慢性病發病率上升、人口老化以及醫療保健支出不斷增加推動了放射性藥物市場的普及。德國、法國和英國因其先進的醫療保健系統和政府支持措施而擁有強大的市場地位。中東和非洲是潛力開拓的新興市場，其特點是醫療基礎設施投資增加和診斷服務需求不斷成長。然而，缺乏熟練的專業人員和各國經濟分散可能對該地區的市場擴張構成挑戰。亞太地區放射性藥物市場正在經歷快速成長，在不斷發展的醫療保健領域擁有強大的研究基礎，提供了巨大的成長機會。中國、日本、澳洲和韓國等國家處於這一成長的前沿。政府加強醫療保健現代化也支持了市場開拓。

FPNV定位矩陣

FPNV定位矩陣對於評估放射性藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對放射性藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估及資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行綜合評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.放射性藥物市場的市場規模與預測為何？

2.在放射性藥物市場的預測期間內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.放射性藥物市場的技術趨勢和法規結構是什麼？

4.放射性藥物市場主要廠商的市場佔有率為何？

5.進入放射性藥物市場的適當型態和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 目標疾病的發生率和盛行率增加
      • 基於α放射免疫療法的標靶癌症治療
      • 努力縮小Mo-99供需缺口
    • 抑制因素
      • 放射性藥物的壽命會縮短。
    • 機會
      • 放射性藥物在神經學應用上的採用
      • 增加診斷中心，特別是在新興國家
    • 任務
      • 設備價格高且醫院預算有限
  • 市場區隔分析
    • 手術數量：近距離放射治療手術的持續進步
    • 應用：提高放射性藥物在治療過程中的使用率
  • 市場趨勢分析
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析
  • 客戶客製化

第6章放射性藥物市場：依類型

  • 核醫學診斷
  • 核子醫學治療

第7章放射性藥物市場：依手術數量分類

  • 診斷
  • 治療

第8章放射性藥物市場：依應用分類

  • 診斷用途
  • 治療用途

第9章美洲放射性藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太放射性藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲放射性藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 百時美施貴寶透過收購 RaysBio 增加了一流的放射性藥物平台
    • 新CRP開發用於疾病診斷的新型Technetium-99m放射性藥物
    • 梅奧診所支持的Start-Ups籌集了 5,600 萬美元，瞄準放射性藥物失敗

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-4308E1C887A3

[191 Pages Report] The Radiopharmaceuticals Market size was estimated at USD 5.15 billion in 2023 and expected to reach USD 5.48 billion in 2024, at a CAGR 6.47% to reach USD 8.00 billion by 2030.

Radiopharmaceuticals are a unique category of medicinal formulations containing radioisotopes that are used in the field of nuclear medicine. These compounds, which are characterized by their ability to emit radiation, serve multiple purposes, including diagnosis, therapy, and research. Radiopharmaceuticals offer significant value in both the detection and treatment of disease, enhancing the capability for early diagnosis, monitoring of disease progression, and effectiveness of therapeutic interventions. Radiopharmaceutical compounds are experiencing significant adoption, driven by the rising prevalence of chronic diseases such as cancer and cardiovascular disorders that require advanced diagnostic techniques. Technological advancements in imaging technologies, such as PET and SPECT, are also catalyzing the radiopharmaceuticals market growth. Additionally, the increasing adoption of personalized medicine and targeted therapy approaches boosts the demand for radioisotopes in therapeutic applications. Despite considerable growth prospects, the radiopharmaceuticals market faces challenges, including stringent regulatory requirements that result in longer approval times for new radiopharmaceuticals. High costs for radiopharmaceutical development and production, as well as the requirement for specialized facilities and trained personnel, add to the list of challenges facing the industry. However, the increasing investment in research and development provides ample opportunities for innovation and expansion in the radiopharmaceutical market. Furthermore, ongoing advancements in theranostics, which combine diagnostic and therapeutic capabilities in a single agent, present new avenues for integrative healthcare solutions and personalized treatment, positioning the radiopharmaceuticals market for sustained growth.

KEY MARKET STATISTICS
Base Year [2023] USD 5.15 billion
Estimated Year [2024] USD 5.48 billion
Forecast Year [2030] USD 8.00 billion
CAGR (%) 6.47%

Procedural Volume: Ongoing advancements in brachytherapy isotopes procedure

Radiopharmaceuticals play a pivotal role in modern medicine, both in diagnostics and therapy. The procedural volume for diagnostic procedures, including PET radiopharmaceuticals and SPECT radiopharmaceuticals, remains significant, owing to their critical function in accurate disease detection and monitoring. PET procedures utilize positron-emitting radiopharmaceuticals, providing high-resolution, functional imaging of processes such as metabolic activity or blood flow. In contrast, SPECT procedures involve gamma-emitting radiopharmaceuticals for mapping physiological functions. In therapeutic procedures, alpha emitters offer advantages owing to the high linear energy transfer and short range, making them effective in treating micrometastases. Beta emitter procedures are more recognized for treating larger volumes of diseased cells due to their broader tissue penetration. Brachytherapy isotope procedures involve implanting radioactive sources directly into or near a tumor, thus delivering localized radiation therapy with minimal impact on surrounding healthy tissue.

Application: Increasing utilization of radiopharmaceuticals in therapeutic procedures

Positron emission tomography (PET) has a crucial role in cardiology by enabling detailed visualization of myocardial perfusion and metabolism. It aids in diagnosing various heart conditions, including coronary artery disease, evaluating myocardial viability, and monitoring heart muscle health post-intervention. In neurology, PET provides valuable insights into cerebral blood flow, glucose metabolism, and amino acid uptake. PET imaging is widely utilized in the evaluation of neurodegenerative diseases, such as Parkinson's disease, epilepsy, and Alzheimer's disease. It aids in early diagnosis, tracking disease progression, and assessing therapeutic interventions, thereby playing a significant role in personalized neurological patient care. PET imaging is crucial in oncology due to its ability to detect and stage cancer with high sensitivity. It assists in pinpointing the location of tumors, understanding their metabolic activity, and evaluating responses to therapy. PET scans guide clinical decision-making in cancer treatment, including surgical planning, radiation therapy, and the assessment of new chemotherapy regimes, thereby offering a path to tailored oncologic interventions.

Single photon emission computed tomography is commonly used in cardiac imaging to evaluate blood flow and examine the pumping function of the heart. It detects areas of ischemia and infarction, assisting clinicians with intervention planning. SPECT imaging has a significant role in the staging and follow-up of lymphoma patients. It allows for the precise localization of lymph nodes and assessment of the disease spread, which is crucial for tailoring the treatment approach. In neurology, SPECT can analyze cerebral blood flow and assess neuronal integrity. It is used in the evaluation of disorders such as stroke, dementia, and seizure disorders, aiding in the determination of functional impairment and treatment efficacy. SPECT is particularly effective in thyroid imaging to evaluate the presence and nature of nodules and in cases of hyperthyroidism. It provides functional information about thyroid activity and assists in the management of thyroid cancer patients, including post-surgical assessment and detection of metastases.

Radiopharmaceuticals play a pivotal role in the palliative treatment of bone metastasis, where metastatic cancer cells have spread to bones. These radioactive compounds, such as Strontium-89 and Samarium-153, are administered to patients, where they selectively localize to areas of increased bone turnover, emitting local radiation that alleviates pain and can reduce the need for opioid analgesics, thereby improving the quality of life in patients with advanced cancers. The management of endocrine tumors, such as neuroendocrine tumors (NETs), has been transformed by the use of radiopharmaceuticals. Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs, such as Lutetium-177 dotatate, targets somatostatin receptors on tumor cells to deliver cytotoxic radiation directly to the tumor, minimizing the exposure to surrounding healthy tissue and offering an effective therapeutic option for inoperable or metastasized NETs. Radiopharmaceutical therapy for lymphoma, particularly non-Hodgkin lymphoma (NHL), incorporates radiolabeled monoclonal antibodies that target CD20 antigens on the surface of malignant cells. Agents such as Ibritumomab Tiuxetan (Zevalin) conjugated with Yttrium-90 deliver targeted radiotherapy to the cancerous cells, which can result in an effective response for patients with refractory to conventional chemotherapy or for those seeking a less aggressive treatment. Radioiodine therapy with Iodine-131 is a well-established treatment for hyperthyroidism and differentiated thyroid cancer. This targeted approach is crucial for differentiated thyroid carcinoma management post-surgery, aiding in both treatment and diagnostic imaging.

Regional Insights

The radiopharmaceutical market in the Americas has shown robust growth, driven by advancements in nuclear medicine and the advanced healthcare infrastructure. The United States contributes majorly to the market with its substantial investments in R&D and favorable reimbursement policies. Canada and Latin America are also experiencing growth, albeit at a slower pace, owing to increasing awareness and improving healthcare facilities. Europe is a significant contributor to the radiopharmaceutical market within the EMEA region, with adoption fuelled by the rising incidence of chronic illnesses, the aging population, and increased healthcare expenditure. Germany, France, and the UK have strong market positions due to their advanced healthcare systems and supportive government initiatives. The Middle East and Africa are emerging markets with untapped potential, characterized by increasing investment in healthcare infrastructure and a growing demand for diagnostic services. However, the scarcity of skilled professionals and economic variability across countries may challenge market expansion in this region. The Asia-Pacific radiopharmaceutical market is experiencing rapid growth, offering substantial opportunities due to its strong research base in evolving healthcare sectors. Countries such as China, Japan, Australia, and South Korea are at the forefront of this growth. The increasing government initiatives to modernize healthcare are propelling market development.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Radiopharmaceuticals Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Radiopharmaceuticals Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Radiopharmaceuticals Market, highlighting leading vendors and their innovative profiles. These include Alliance Holdings Medical Limited, Bayer AG, Bracco Group, BWX Technologies. Inc., BWXT Medical Ltd., Cardinal Health, Inc., Clarity Pharmaceuticals, Curium Pharma, Eckert & Ziegler Group, Eczacibasi-Monrol Nuclear Products Co., Fusion Pharmaceuticals Inc., GE HealthCare Technologies, Inc., Global Medical Solutions, Institute of Isotopes Co. Ltd., International Isotopes, Inc., IsoTherapeutics Group, LLC, Isotopia Molecular Imaging Ltd., Jubilant Pharma Holdings Inc., Lantheus Medical Imaging, Inc., Mallinckrodt PLC, Medi-Radiopharma, Northstar Medical Technologies LLC, Novartis AG, NTP Radioisotopes SOC Ltd., SHINE Medical Technologies, Siemens Healthineers AG, Sinotau Pharmaceutical Group, and State Atomic Energy Corporation Rosatom.

Market Segmentation & Coverage

This research report categorizes the Radiopharmaceuticals Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Diagnostic Nuclear Medicine
      • Pet Radiopharmaceuticals
        • F-18
        • Ru-82
      • Spect Radiopharmaceuticals
        • Ga-67
        • I-123
        • Tc-99m
        • Tl-201
    • Therapeutic Nuclear Medicine
      • Alpha Emitters
      • Beta Emitters
        • I-131
        • Lu-177
        • Re-186
        • Sm-153
        • Y-90
      • Brachytherapy Isotopes
        • Cs-131
        • I-125
        • Ir-192
        • Pd-103
  • Procedural Volume
    • Diagnostic Procedures
      • Pet Radiopharmaceutical Procedure
      • Spect Radiopharmaceuticals Procedure
    • Therapeutic Procedures
      • Alpha Emitter Procedure
      • Beta Emitters Procedure
      • Brachytherapy Isotopes Procedure
  • Application
    • Diagnostic Applications
      • Pet Applications
        • Cardiology Indication
        • Neurology Indication
        • Oncology Indication
      • Spect Applications
        • Cardiology
        • Lymphoma
        • Neurology
        • Thyroid
    • Therapeutic Applications
      • Bone Metastasis
      • Endocrine Tumors
      • Lymphoma Therapeutic
      • Thyroid Therapeutic
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Radiopharmaceuticals Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Radiopharmaceuticals Market?

3. What are the technology trends and regulatory frameworks in the Radiopharmaceuticals Market?

4. What is the market share of the leading vendors in the Radiopharmaceuticals Market?

5. Which modes and strategic moves are suitable for entering the Radiopharmaceuticals Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Incidence and Prevalence of Target Conditions
      • 5.1.1.2. Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
      • 5.1.1.3. Initiatives To Reduce The Demand-Supply Gap of mo-99
    • 5.1.2. Restraints
      • 5.1.2.1. Shorter Life of Radiopharmaceuticals
    • 5.1.3. Opportunities
      • 5.1.3.1. Adoption of Radiopharmaceuticals in Neurological Applications
      • 5.1.3.2. Rising Number of Diagnostic Centers Especially in Developing Countries
    • 5.1.4. Challenges
      • 5.1.4.1. High Equipment Prices and Limited Hospital Budget
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Procedural Volume: Ongoing advancements in brachytherapy isotopes procedure
    • 5.2.2. Application: Increasing utilization of radiopharmaceuticals in therapeutic procedures
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Radiopharmaceuticals Market, by Type

  • 6.1. Introduction
  • 6.2. Diagnostic Nuclear Medicine
  • 6.3. Therapeutic Nuclear Medicine

7. Radiopharmaceuticals Market, by Procedural Volume

  • 7.1. Introduction
  • 7.2. Diagnostic Procedures
  • 7.3. Therapeutic Procedures

8. Radiopharmaceuticals Market, by Application

  • 8.1. Introduction
  • 8.2. Diagnostic Applications
  • 8.3. Therapeutic Applications

9. Americas Radiopharmaceuticals Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Radiopharmaceuticals Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Radiopharmaceuticals Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
    • 12.3.2. New CRP to Develop new Technetium-99m Radiopharmaceuticals for Disease Diagnosis
    • 12.3.3. With USD 56 Million, a Mayo Clinic-backed Startup takes aim at Radiopharmaceutical Roadblocks

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. RADIOPHARMACEUTICALS MARKET RESEARCH PROCESS
  • FIGURE 2. RADIOPHARMACEUTICALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. RADIOPHARMACEUTICALS MARKET DYNAMICS
  • FIGURE 7. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. RADIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. RADIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RADIOPHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY F-18, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY F-18, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RU-82, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RU-82, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GA-67, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GA-67, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-123, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-123, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TC-99M, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TC-99M, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TL-201, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TL-201, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-131, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-131, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LU-177, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LU-177, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RE-186, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RE-186, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SM-153, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SM-153, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY Y-90, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY Y-90, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CS-131, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CS-131, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-125, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-125, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IR-192, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IR-192, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PD-103, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PD-103, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 70. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 71. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICAL PROCEDURE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 72. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICAL PROCEDURE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 73. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS PROCEDURE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 74. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS PROCEDURE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 75. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 76. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 77. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 78. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 79. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTER PROCEDURE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 80. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTER PROCEDURE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 81. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS PROCEDURE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 82. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS PROCEDURE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 83. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES PROCEDURE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 84. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES PROCEDURE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 85. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 88. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 89. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 90. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 91. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 92. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 93. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 94. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 95. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY INDICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 96. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY INDICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 97. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY INDICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 98. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY INDICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 99. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY INDICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 100. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY INDICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 101. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 102. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 103. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 104. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 105. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 106. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 107. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 108. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 109. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 110. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 111. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THYROID, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 112. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THYROID, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 113. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 114. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 115. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 116. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 117. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BONE METASTASIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 118. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BONE METASTASIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 119. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINE TUMORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 120. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINE TUMORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 121. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LYMPHOMA THERAPEUTIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 122. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LYMPHOMA THERAPEUTIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 123. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THYROID THERAPEUTIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 124. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THYROID THERAPEUTIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 125. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 128. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 129. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 130. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 131. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 132. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 133. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 134. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 135. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
  • TABLE 136. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
  • TABLE 137. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
  • TABLE 138. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
  • TABLE 139. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
  • TABLE 140. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
  • TABLE 141. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 142. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 143. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 144. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 145. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 148. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 149. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 150. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 151. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 152. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 153. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 154. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 155. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 160. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 161. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 162. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 163. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 164. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 165. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 166. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 167. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
  • TABLE 168. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
  • TABLE 169. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
  • TABLE 170. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
  • TABLE 171. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
  • TABLE 172. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
  • TABLE 173. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 174. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 175. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 176. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 177. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 180. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 181. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 182. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 183. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 184. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 185. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 186. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 187. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 190. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 191. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 192. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 193. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 194. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 195. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 196. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 197. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
  • TABLE 198. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
  • TABLE 199. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
  • TABLE 200. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
  • TABLE 201. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
  • TABLE 202. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
  • TABLE 203. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 204. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 205. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 206. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 207. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 210. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 211. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 212. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 213. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 214. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 215. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 216. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 217. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 220. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 221. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 222. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 223. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 224. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 225. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 226. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 227. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
  • TABLE 228. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
  • TABLE 229. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
  • TABLE 230. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
  • TABLE 231. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
  • TABLE 232. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
  • TABLE 233. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 234. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 235. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 236. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 237. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 240. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 241. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 242. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 243. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 244. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 245. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 246. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 247. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 250. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 251. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 252. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 253. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 254. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 255. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 256. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 257. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
  • TABLE 258. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
  • TABLE 259. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
  • TABLE 260. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
  • TABLE 261. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
  • TABLE 262. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
  • TABLE 263. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 264. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 265. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 266. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 267. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 268. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 269. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 270. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 271. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 272. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 273. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 274. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 275. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 276. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 285. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 286. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 287. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
  • TABLE 288. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
  • TABLE 289. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
  • TABLE 290. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
  • TABLE 291. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
  • TABLE 292. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
  • TABLE 293. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 294. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 295. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 296. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 297. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 298. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 299. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 300. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 301. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 302. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 303. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 304. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 305. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 306. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 307. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 308. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC